Close
18/03/2014
The public-private partnership ESTEVE-UAB is bearing fruit
ESTEVE has announced the signing of two agreements that will enable it to progress the development of its gene therapeutic for the treatment of Sanfilippo A Syndrome and begin a phase I/II clinical trial in 2015. The agreements are with the North American biotechnology company REGENX Biosciences, LLC (REGENX) and with the French non for profit organization GÉNÉTHON.
 
Sanfilippo A is a rare and devastating neurodegenerative disease that affects approximately 1 in every 100.000 children that rarely survive past adolescence.

This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fàtima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona (UAB).

In this partnership, ESTEVE leads all activities associated with the management and protection of intellectual property, regulatory activities, the coordination and supervision of GMP manufacturing, the preclinical toxicology studies as well as all clinical development.
The CBATEG research team at the UAB brings to the partnership their scientific know-how and expertise in gene therapy including viral vector design and the development of preclinical disease models.

Press release

More news

17/02/2016 Barcelona Synchrotron Park, a Park with a (Pre)History 10/02/2016 New mechanism of anti-tumour action for the new drug developped at the UAB 03/02/2016 Step in Barcelona 27/01/2016 ALBA News 21/01/2016 SENER celebrates its 60th anniversary 15/01/2016 Parc Tecnològic del Vallès: Arrival of FERRER and Accreditation of SEVIBE CELLS
27 28 29 30 31 32 33 34 35 36 37